MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Raptor Pharmaceutical Corp. Company Profile (NASDAQ:RPTP)

Consensus Ratings for Raptor Pharmaceutical Corp. (NASDAQ:RPTP) (?)
Ratings Breakdown: 4 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $11.00 (105.61% upside)

Analysts' Ratings History for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
Show:
DateFirmActionRatingPrice TargetActions
6/12/2016FBR & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016WedbushReiterated RatingNeutral$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Leerink SwannReiterated RatingOutperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016OppenheimerReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2016JMP SecuritiesDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016Citigroup Inc.UpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/22/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.17)($0.17)$27.17 million$27.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.19)($0.17)$26.08 million$24.67 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.18)($0.18)$24.25 million$25.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.21)($0.12)$21.40 million$23.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.25)($0.24)$19.10 million$20.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.14)($0.25)$20.12 million$17.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.18)($0.04)$18.90 million$23.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.19)($0.15)$14.58 million$16.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q413($0.17)($0.20)$11.81 million$12.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q313($0.18)($0.19)$10.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.30)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2013Q1 2013($0.27)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/9/2013Q1 2013($0.23)($0.26)$0.25 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q412($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.17)($0.15)($0.16)
Q2 20163($0.15)($0.14)($0.15)
Q3 20162($0.21)($0.15)($0.18)
Q4 20163($0.21)($0.14)($0.18)
(Data provided by Zacks Investment Research)
Dividend History for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/9/2015Suzanne Louise BruhnDirectorSell18,258$12.47$227,677.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Raymond AndersonDirectorSell4,916$12.51$61,499.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Raymond AndersonDirectorSell8,084$12.52$101,211.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Llew KeltnerDirectorSell50,000$16.05$802,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Thomas E DaleyInsiderSell35,000$15.00$525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Suzanne Louise BruhnDirectorSell30,000$13.45$403,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Richard L FranklinDirectorSell10,000$9.61$96,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Richard L FranklinDirectorSell10,000$10.37$103,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Christopher M StarrDirectorSell20,033$11.62$232,783.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Richard L FranklinDirectorSell10,000$9.18$91,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Christopher M StarrDirectorSell30,000$9.52$285,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Richard L FranklinDirectorSell7,109$9.20$65,402.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2015Christopher M StarrDirectorSell30,000$9.45$283,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Christopher M StarrDirectorSell30,000$9.73$291,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Raymond AndersonDirectorSell10,000$10.58$105,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Christopher M StarrCEOSell30,000$9.00$270,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Christopher M StarrCEOSell30,000$8.15$244,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Christopher M StarrCEOSell30,000$9.97$299,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2014Christopher M StarrCEOSell30,000$10.25$307,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Christopher M StarrCEOSell30,000$10.21$306,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Christopher M StarrCEOSell32,896$10.60$348,697.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Raymond AndersonDirectorSell10,000$10.81$108,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Erich SagerDirectorSell10,000$11.01$110,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Llew KeltnerDirectorSell10,000$11.21$112,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Georgia ErbezCFOBuy16,100$7.90$127,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Vijay SamantDirectorSell5,000$8.59$42,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Christopher StarrCEOSell19,316$10.79$208,419.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Timothy WalbertDirectorSell5,520$15.06$83,131.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2014Thomas DaleyInsiderSell15,000$14.17$212,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Llew KeltnerDirectorSell10,000$13.25$132,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Richard FranklinDirectorSell10,715$13.12$140,580.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Vijay SamantDirectorSell5,000$13.86$69,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Timothy WalbertDirectorSell5,521$12.44$68,681.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2013Richard FranklinDirectorSell10,715$14.88$159,439.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Christopher M StarrCEOSell25,000$13.77$344,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Suzanne Louise BruhnDirectorSell2,760$13.58$37,480.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2013Vijay SamantDirectorSell5,000$14.76$73,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Christopher StarrCEOSell25,000$14.21$355,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Erich SagerDirectorSell17,000$14.21$241,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Suzanne Louise BruhnDirectorSell2,760$14.07$38,833.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013Richard L FranklinDirectorSell10,715$14.24$152,581.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013Thomas E DaleyInsiderSell25,000$14.28$357,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Georgia ErbezCFOSell7,400$13.42$99,308.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2012Raymond AndersonDirectorSell2,000$5.50$11,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Erich SagerDirectorSell11,279$5.00$56,395.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2012Raymond AndersonDirectorSell2,000$5.50$11,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
DateHeadline
06/29/16 08:57 AMCovering the Bases on Raptor Pharmaceutical Corp. (NASDAQ:RPTP): Where is the Stock Going? - Press Telegraph
06/29/16 08:57 AMRaptor Pharmaceutical Corp. (RPTP) Updated Price Targets - FTSE News
06/26/16 05:12 PMStrong Sell Calls Recommendations For Raptor Pharmaceutical Corp. (NASDAQ:RPTP) At 0 - Investor Newswire
06/26/16 05:12 PMRaptor Pharmaceutical Corp. (RPTP) Jumps 6.43% on June 23 - Equities.com
06/23/16 01:29 PMRaptor Pharmaceutical Corp. – Value Analysis (NASDAQ:RPTP) : June 23, 2016 -
06/23/16 08:51 AMRaptor Pharmaceutical Corp. (RPTP) Drops 5.74% on June 21 - Equities.com
06/22/16 06:09 PMRaptor Pharmaceutical (NASDAQ:RPTP) Analyst Rating Consensus - TheFounders Daily
06/22/16 06:09 PMRaptor Pharmaceuticals Corp. (NasdaqGM:RPTP) Stock Momentum at Critical Inflection Point - CML News
06/22/16 07:18 AMRaptor Pharmaceutical Corp. breached its 50 day moving average in a Bearish Manner : RPTP-US : June 22, 2016 -
06/20/16 07:45 AMThis Weeks Broker Views For Raptor Pharmaceutical Corp. (RPTP) - Fiscal Standard
06/19/16 09:59 AMStrong Buy Calls Count For Raptor Pharmaceutical Corp. (NASDAQ:RPTP) At 3 - Investor Newswire
06/14/16 06:49 AMRaptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference - [at noodls] - NOVATO, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith, President and ...
06/11/16 09:05 AMRaptor Pharma Reports Data from Phase 3 Study of QUINSAIR
06/11/16 09:05 AMNovato’s Raptor Pharmaceuticals reports fewer lung issues in cystic fibrosis patients with its drug
06/10/16 07:09 AMRaptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR™ at the 39th European Cystic Fibrosis Conference - [at noodls] - NOVATO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today ...
06/10/16 07:06 AM8:06 am Raptor Pharma announces new data analyses of its Phase 3 clinical study (MPEX-209) comparing QUINSAIRTM to inhaled tobramycin solution in patients with cystic fibrosis at the European Cystic Fibrosis Conference -
06/08/16 06:42 PMRAPTOR PHARMACEUTICALS CORP. (NASDAQ:RPTP) Financial Condition Compared to S&P 500 - CML News
06/08/16 09:12 AMAnother Look At Raptor Pharmaceutical Corp. - Seeking Alpha
06/07/16 03:28 PMRaptor Pharmaceutical to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference - [at noodls] - NOVATO, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today ...
06/06/16 06:08 PMAnother Look At Raptor Pharmaceuticals - Seeking Alpha
05/31/16 06:31 PMShare Rating Focus on Raptor Pharmaceutical Corp. (NASDAQ:RPTP) - HNN - Share Rating Focus on Raptor Pharmaceutical Corp. (NASDAQ:RPTP)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 2 on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP). Covering analysts will ...and more »
05/31/16 06:31 PMNews Sentiment For Raptor Pharmaceutical Corp. (NASDAQ:RPTP) - Investor Newswire - News Sentiment For Raptor Pharmaceutical Corp. (NASDAQ:RPTP)Investor NewswireRaptor Pharmaceutical Corp. (NASDAQ:RPTP) Average broker stands at 2 while it was 2 three months ago. The quarterly report of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) can be made public close to 2016-08-04. It is estimated by the recent update ...and more »
05/31/16 09:44 AMStock's Move to Focus: Raptor Pharmaceutical Corp. (NASDAQ:RPTP) , Becton, Dickinson and Company (NYSE:BDX) - Street Updates - Stock's Move to Focus: Raptor Pharmaceutical Corp. (NASDAQ:RPTP) , Becton, Dickinson and Company (NYSE:BDX)Street UpdatesIn the liquidity ratio analysis; Raptor Pharmaceuticals Corp.'s (RPTP) debt to equity ratio was 1.33 while current ratio was 4.20. The company has the institutional ownership of 63.60% while the Beta factor was 1.25. The stock's RSI amounts to 62.49 ...and more »
05/29/16 11:31 PMRaptor Pharmaceutical Corporation (NASDAQ:RPTP) Shorted Shares Increased By 5.17% - HNN - Raptor Pharmaceutical Corporation (NASDAQ:RPTP) Shorted Shares Increased By 5.17%HNNThe stock of Raptor Pharmaceutical Corporation (NASDAQ:RPTP) registered an increase of 5.17% in short interest. RPTP's total short interest was 6.42 million shares in May as published by FINRA. Its up 5.17% from 6.10M shares, reported previously.
05/24/16 10:29 AMRaptor Pharmaceutical Corp. Just Recorded A Sigfniciant Decline - Wall Street Hints and News - Raptor Pharmaceutical Corp. Just Recorded A Sigfniciant DeclineWall Street Hints and NewsThe stock of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) is a huge mover today! The stock decreased 2.69% or $0.14 during the last trading session, hitting $5.06. About 384,322 shares traded hands. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) has ...
05/22/16 05:57 PMNext Weeks Broker Price Targets For Raptor Pharmaceutical Corp. (RPTP) - Share Trading News - Next Weeks Broker Price Targets For Raptor Pharmaceutical Corp. (RPTP)Share Trading News04/07/2016 – Raptor Pharmaceutical Corp. was upgraded to “market outperform” by analysts at JMP Securities. They now have a USD 9 price target on the stock. 02/26/2016 – Raptor Pharmaceutical Corp. had its “outperform” rating reiterated by analysts at ...and more »
05/20/16 10:21 AMNotable Thursday Option Activity: RPTP, WBC, TTWO - Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Raptor Pharmaceuticals Corp. (Symbol: RPTP), where a total of 3,168 contracts have traded so far, representing approximately 316,800 underlying shares.
05/19/16 06:32 PMRevenue Update on Raptor Pharmaceutical Corp.(NASDAQ:RPTP) - Trade Calls - Revenue Update on Raptor Pharmaceutical Corp.(NASDAQ:RPTP)Trade CallsRaptor Pharmaceutical Corp.(NASDAQ:RPTP) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 5, 2016. Company reported revenue of $27.47M. Analysts estimated a revenue of $27.17M. Earnings ...Raptor Pharmaceutical Corp. (NASDAQ:RPTP): Stock Rating and Earnings ReviewFranklin IndependentRaptor Pharmaceutical Corp. (NASDAQ:RPTP) Hovering Around $4.78Equities FocusAnalyst Recommendations On Raptor Pharmaceutical Corp. (NASDAQ:RPTP)News Tribuneall 5 news articles »
05/19/16 10:01 AMTraders Checklist Stocks: Arrowhead Research Corporation (NASDAQ:ARWR) , Raptor Pharmaceutical Corp ... - Street Updates - Traders Checklist Stocks: Arrowhead Research Corporation (NASDAQ:ARWR) , Raptor Pharmaceutical Corp ...Street UpdatesRaptor Pharmaceutical Corp. (NASDAQ:RPTP) moved in green zone with rise of +0.06 points or +1.27% to $4.78. The company has a market worth of $407.76M.Total 502.39 thousand shares were exchanged in last trading session as opposed to average ...and more »
05/17/16 07:19 AMRaptor Pharmaceutical Corp. breached its 50 day moving average in a Bullish Manner : RPTP-US : May 17, 2016 -
05/13/16 12:04 PMRAPTOR PHARMACEUTICAL CORP Financials -
05/12/16 03:52 PMETF’s with exposure to Raptor Pharmaceutical Corp. : May 12, 2016 -
05/11/16 11:16 AMRaptor Pharmaceutical Corp. :RPTP-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 06:52 PMConsensus Rating Review for Raptor Pharmaceutical Corp. (NASDAQ:RPTP) - B.O.D.Y Confidential - Consensus Rating Review for Raptor Pharmaceutical Corp. (NASDAQ:RPTP)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 2 on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/07/16 06:04 PMAnalyst's Valuable Buzzers: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) , Raptor Pharmaceutical Corp. (NASDAQ:RPTP) - Street Updates - Analyst's Valuable Buzzers: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) , Raptor Pharmaceutical Corp. (NASDAQ:RPTP)Street UpdatesRaptor Pharmaceutical Corp. (NASDAQ:RPTP) moved in red zone with decline of -0.15 points or -3.33% to $4.35. The company has a market worth of $370.77M.Total 887.88 thousand shares were exchanged in last trading session as opposed to average ...and more »
05/06/16 06:49 PMAttentive Stocks in Active Notes- Raptor Pharmaceuticals (NASDAQ:RPTP), Genworth Financial (NYSE:GNW ... - Seneca Globe - Attentive Stocks in Active Notes- Raptor Pharmaceuticals (NASDAQ:RPTP), Genworth Financial (NYSE:GNW ...Seneca GlobeRaptor Pharmaceuticals Corp. (NASDAQ:RPTP) plummeted -3.85% to trade at $4.50 with shares volume of 599024. Raptor Pharmaceutical Corp. (RPTP) reported that a loss of $41.6 million in its first quarter. On a per-share basis, the Novato, ...and more »
05/06/16 03:28 PMEdited Transcript of RPTP earnings conference call or presentation 5-May-16 8:30pm GMT -
05/06/16 07:27 AMRaptor Pharmaceutical Corp. breached its 50 day moving average in a Bearish Manner : RPTP-US : May 6, 2016 -
05/06/16 12:17 AMEARNINGS SUMMARY: Details of Raptor Pharmaceuticals Corp. Q1 Earnings Report - Below are the earnings highlights for Raptor Pharmaceuticals Corp. (RPTP): -Earnings: -$14.06 million in Q1 vs. -$16.83 million in the same period last year. -EPS: -$0.17 in Q1 vs. -$0.24 in the same period last year. -Revenue: $27.47 million in Q1 vs.
05/05/16 07:08 PMEarnings Outlook on Raptor Pharmaceutical Corp. (NASDAQ:RPTP) - B.O.D.Y Confidential - Earnings Outlook on Raptor Pharmaceutical Corp. (NASDAQ:RPTP)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Raptor Pharmaceutical Corp. (NASDAQ:RPTP)'s next earnings release which is expected to be posted on or around 2016-05-05. Sell-side research firms on Wall Street are expecting that the company will post EPS ...and more »
05/05/16 06:42 PMRaptor Pharmaceutical reports 1Q loss -
05/05/16 03:30 PMRaptor Pharmaceutical Corp Earnings Call scheduled for 4:30 pm ET today -
05/05/16 03:21 PMRaptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results - [at noodls] - PROCYSBIGlobal Net Revenue Increased 34% Year-Over-Year, to $27.5 Million 2016 Non-GAAP Operating Expense Guidance Lowered to $125 - $135 Million Full-Year 2016 Revenue Guidance Maintained at $115 - $125 ...
05/05/16 03:02 PMRAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
05/05/16 06:07 AMQ1 2016 Raptor Pharmaceutical Corp Earnings Release - After Market Close -
05/02/16 07:23 PMRaptor Pharmaceutical Corporation (NASDAQ:RPTP) Shorts Decreased by 17.36% After Short Covering - B.O.D.Y Confidential - Raptor Pharmaceutical Corporation (NASDAQ:RPTP) Shorts Decreased by 17.36% After Short CoveringB.O.D.Y ConfidentialThe stock of Raptor Pharmaceutical Corporation (NASDAQ:RPTP) registered a decrease of 17.36% in short interest. RPTP's total short interest was 6.30 million shares in May as published by FINRA. Its down 17.36% from 7.63 million shares, reported ...
04/29/16 06:55 PMRaptor Pharmaceutical Corp. (RPTP) Updated Broker Price Targets - Share Trading News - Raptor Pharmaceutical Corp. (RPTP) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Raptor Pharmaceutical Corp. (RPTP). The latest reports which are currently in issue on Friday 29th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/28/16 06:57 AMRaptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET - [at noodls] - NOVATO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5, 2016, ...
03/21/16 03:23 PMRaptor's PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review - [at noodls] - NOVATO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI (cysteamine ...
03/21/16 03:05 PMRaptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review - [GlobeNewswire] - NOVATO, Calif., March 21, 2016-- Raptor Pharmaceutical Corp. today announced that Health Canada has accepted for review its New Drug Submission for PROCYSBI ® delayed-release capsules for the treatment ...
About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. logoRaptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company's pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RPTP
  • CUSIP: 75382F10
Key Metrics:
  • Previous Close: $5.35
  • 50 Day Moving Average: $5.18
  • 200 Day Moving Average: $4.62
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $456.39M
  • Current Quarter EPS Consensus Estimate: $-0.97 EPS
Additional Links:
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha